Pelvic floor dysfunction in women with fibromyalgia and control subjects: Prevalence and impact on overall symptomatology and psychosocial function. Issue 8 (4th July 2018)

• Record Type: Journal Article
• Authors: Carrillo‐Izquierdo, Maria Dolores; Slim, Mahmoud; Hidalgo‐Tallon, Javier; Calandre, Elena P.
• Is Part Of: Neurourology and urodynamics. Volume 37:Issue 8(2018:Nov.)
• Page Start: 2702
• Page End: 2709
• Publication Date: 2018-07-04
• Subjects: controls -- fecal incontinence -- fibromyalgia -- pelvic floor dysfunction -- pelvic organ prolapse -- prevalence -- psychosocial function -- urinary incontinence; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.23723
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract : Aims: To evaluate the prevalence, distress, and impact of pelvic floor dysfunction (PFD) symptomatology in women with fibromyalgia and control women. We also aimed to evaluate the impact of PFD symptomatology on several psychosocial measures such as mood, sleep, pain, and quality of life. Methods: We conducted a cross‐sectional study in women with fibromyalgia and control women from the general population. Using a structured survey, we collected sociodemographic and clinical data, assessed the prevalence of PFD and evaluated the distress (PFDI‐20) and the impact (PFIQ‐7) caused by its symptomatology. Using Spanish‐validated questionnaires, we also evaluated mood and sleep disturbances, bodily pain, and quality of life in subjects with and without PFD. In participants with fibromyalgia, we assessed the severity and impact of the disease using the Fibromyalgia Impact Questionnaire (FIQR). Results: Two hundred and twenty‐six patients with fibromyalgia and 222 control women completed the surveys. Two hundred and twenty patients (93%) and 140 controls (63%) reported PFD‐related symptoms. Both the scores of distress (143.1 ± 5.7 vs 96.1 ± 4.8, P < 0.0001) and impact (122.4 ± 5.6 vs 100.6 ± 6.4, P < 0.0001) caused by PFD symptoms were significantly higher in women with fibromyalgia than in controls. There was a significant positive relationship between fibromyalgia severity and both PFDI‐20 ( r 2 = 0.32, P < 0.0001) and PFIQ‐7 scores ( r 2 = 0.375, P < 0.0001). Depression severity, sleep disturbances, bodily pain, and low quality of life were highest in women with fibromyalgia and PFD and lowest in control women without PFD. Conclusions: PFD‐related symptoms were significantly more frequent in women with fibromyalgia than in controls. PFD symptomatology, when present, negatively influenced mood, sleep quality, and quality of life of both patients with fibromyalgia and controls.